Abstract

Localized scleroderma is an infrequent disease in children, but still ten times more frequent than systemic sclerosis. The incidence is probably 5-10/100,000 per year. The disease is classified into five subgroups. Paediatric rheumatologists report linear scleroderma as the most frequent subgroup whereas plaque morphea is found most frequently by dermatologists, linear scleroderma being in second place. The risk of transforming into systemic sclerosis is minimal. The mortality risk is not found increased compared with the normal population. Systemic sclerosis is the most infrequent systemic connective tissue disease in children, the incidence is less than 1/1,000,000 per year. The outcome in children is considered to be generally better than in adults. However, deaths is caused most frequently by heart failure with or without pulmonal hypertension, but also by renal or respiratory insuffiency, CNS disease and sepsis. Cumulative survival after 5, 10, 15 and 20 years of disease is reported to be 89%, 80%, 74% and 69%. For the age group less than 16 years the median age of death is reported to be 10.4 years, range 5 to 15 years. The disease in the children who die is often rapidly progressing with early involvement of internal organs.

Highlights

  • Localized scleroderma is an infrequent disease in children, but still ten times more frequent than systemic sclerosis

  • Den dominerende sykdom hos barn og unge er lokalisert sklerodermi som i motsetning til systemisk sklerose nesten aldri angriper indre organer

  • Martini G, Foeldvari I, Russo R et al Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database

Read more

Summary

ENGLISH SUMMARY

Den dominerende sykdom hos barn og unge er lokalisert sklerodermi som i motsetning til systemisk sklerose nesten aldri angriper indre organer. Men trolig opptrer lokalisert sklerodermi 10 ganger hyppigere enn systemisk sklerose som man antar opptrer hos

Lokalisert sklerodermi
Findings
Systemisk sklerose
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.